NHS-approved digital therapeutics company, my mhealth, with three European collaborators, have been awarded a €2.5m Eurostars Grant for the development of their innovative project, CUOREMA.
Eurostars is a European joint programme, co-funded from the national budgets of 36 EUREKA countries and by the European Union through Horizon 2020.
As a UK funding body, Innovate UK will sponsor my mhealth Limited to develop part of its myHeart app to support cardiac rehabilitation in Europe.
Together with three accomplished European partners; Ospedale Malcantonese (OSCAM) (Switzerland), Games for Health (The Netherlands) and the University of Applied Sciences and Arts of Southern Switzerland (SUPSI) (Switzerland), the project aims to utilise the cardiac rehabilitation element of the myHeart app and incorporate biofeedback, intelligent algorithms and gamification features.
During the three years of planning and development, the platform will be formally researched in the UK and several European countries through formal clinical trials.
The CUOREMA project will focus on developing a new, patient-centred and intelligent cardiac rehabilitation support system. The scalable, customisable, and flexible technology will provide a new systematic method of social and biological feedback from wearable devices, the app will include built-in behaviour change support systems, with mixed reality and immersive technology to improve medical adherence and clinical outcomes.
The Eurostars Programme is a funding and support programme, aimed at R&D-performing SMEs that wish to redeem the benefits that come with international collaboration.
Dr. Simon Bourne, Chief Executive Officer of my health, said: “We are thrilled to be partnering with such talented and diverse teams on this innovative and important project over the next few years. Each organisation brings a very unique perspective to the table, allowing for a thoughtful and comprehensive approach to tackling heart health. I am extremely passionate about digital health and this has the potential to change many lives for the better, helping us transform cardiac rehabilitation for patients across Europe.”